title: Risk of meningioma and common variation in genes related to innate immunity.
abstract: BACKGROUND
  The etiology of meningioma, the second most common type of adult brain tumor in the United States, is largely unknown. Prior studies indicate that history of immune-related conditions may affect the risk of meningioma.
  
  
  METHODS
  To identify genetic markers for meningioma in genes involved with innate immunity, we conducted an exploratory association study of 101 meningioma cases and 330 frequency-matched controls of European ancestry using subjects from a hospital-based study conducted by the National Cancer Institute. We genotyped 1,407 "tag" single nucleotide polymorphisms (SNP) in 148 genetic regions chosen on the basis of an r2>0.8 and minor allele frequency of >5% in Caucasians in HapMap1. Risk of meningioma was estimated by odds ratios and 95% confidence intervals.
  
  
  RESULTS
  Seventeen SNPs distributed across 12 genetic regions (NFKB1 (3), FCER1G (3), CCR6 (2), VCAM1, CD14, TNFRSF18, RAC2, XDH, C1D, TLR1/TLR10/TLR6, NOS1, and DEFA5) were associated with the risk of meningioma with P<0.01. Although individual SNP tests were not significant after controlling for multiple comparisons, gene region-based tests were statistically significant (P<0.05) for TNFRSF18, NFKB1, FCER1G, CD14, C1D, CCR6, and VCAM1.
  
  
  CONCLUSIONS
  Our results indicate that common genetic polymorphisms in innate immunity genes may be associated with risk of meningioma. Given the small sample size, replication of these results in a larger study of meningioma is needed.
authors.affiliation: Division of Cancer Epidemiology and Genetics, Neuro-oncology Branch, National Cancer Institute, NIH, Department of Health and Human Services, 6120 Executive Boulevard, EPS Room 7058, Bethesda, MD 20892-7238, USA. rajarama@mail.nih.gov
authors.forename: Preetha
authors.initials: P
authors.lastname: Rajaraman
authors.forename: Alina V
authors.initials: AV
authors.lastname: Brenner
authors.forename: Gila
authors.initials: G
authors.lastname: Neta
authors.forename: Ruth
authors.initials: R
authors.lastname: Pfeiffer
authors.forename: Sophia S
authors.initials: SS
authors.lastname: Wang
authors.forename: Meredith
authors.initials: M
authors.lastname: Yeager
authors.forename: Gilles
authors.initials: G
authors.lastname: Thomas
authors.forename: Howard A
authors.initials: HA
authors.lastname: Fine
authors.forename: Martha S
authors.initials: MS
authors.lastname: Linet
authors.forename: Nathaniel
authors.initials: N
authors.lastname: Rothman
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Chanock
authors.forename: Peter D
authors.initials: PD
authors.lastname: Inskip
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics*; D008297:Male; D008577:Meningeal Neoplasms / Q000235:genetics* / Q000276:immunology*; D008579:Meningioma / Q000235:genetics* / Q000276:immunology*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D055815:Young Adult
chemical_list: D009363:Neoplasm Proteins
references.citation: PLoS One. 2009;4(4):e5360
references.pmid: 19390683
references.citation: Neurotherapeutics. 2009 Jul;6(3):427-35
references.pmid: 19560733
references.citation: Cancer Lett. 2002 Dec 15;188(1-2):103-7
references.pmid: 12406554
references.citation: Pharmacogenet Genomics. 2006 Nov;16(11):783-8
references.pmid: 17047486
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):976-86
references.pmid: 19223558
references.citation: Genet Epidemiol. 2003 Dec;25(4):360-6
references.pmid: 14639705
references.citation: Neurosurgery. 2000 Nov;47(5):1185-95
references.pmid: 11063113
references.citation: J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50
references.pmid: 17925535
references.citation: Nat Rev Immunol. 2005 Nov;5(11):866-79
references.pmid: 16261174
references.citation: Immunol Rev. 2006 Oct;213:195-212
references.pmid: 16972905
references.citation: J Anat. 2005 Sep;207(3):265-9
references.pmid: 16185251
references.citation: N Engl J Med. 2001 Jan 11;344(2):79-86
references.pmid: 11150357
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1651-8
references.pmid: 19423540
references.citation: Nature. 2003 Dec 18;426(6968):789-96
references.pmid: 14685227
references.citation: Cancer. 1999 Dec 15;86(12):2649-58
references.pmid: 10594860
references.citation: Am J Epidemiol. 2007 Mar 1;165(5):477-85
references.pmid: 17182979
references.citation: J Immunol. 2009 Mar 1;182(5):3131-8
references.pmid: 19234210
references.citation: Histol Histopathol. 2007 Dec;22(12):1387-98
references.pmid: 17701919
references.citation: PLoS Genet. 2008 Aug;4(8):e1000166
references.pmid: 18846228
references.citation: Dement Geriatr Cogn Disord. 2008;26(3):247-50
references.pmid: 18841008